As of today (2024-04-16), Vertex Pharmaceuticals's share price is $397.36. Vertex Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $60.74. Hence, Vertex Pharmaceuticals's Price to Tangible Book Ratio of today is 6.54.
The historical rank and industry rank for Vertex Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:
VRTX'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.07 Med: 10.88 Max: 51.21
Current: 6.54
During the past 13 years, Vertex Pharmaceuticals's highest Price to Tangible Book Ratio was 51.21. The lowest was 6.07. And the median was 10.88.
VRTX's Price-to-Tangible-Book is ranked worse than 79.62% of 1222
companies
in the Biotechnology industry
Industry Median: 2.75
vs VRTX: 6.54
A closely related ratio is called PB Ratio. As of today, Vertex Pharmaceuticals's share price is $397.36. Vertex Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $68.22. Hence, Vertex Pharmaceuticals's P/B Ratio of today is 5.82.
Vertex Pharmaceuticals Price-to-Tangible-Book Historical Data
The historical data trend for Vertex Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Vertex Pharmaceuticals Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Price-to-Tangible-Book
12.11
8.43
6.42
6.07
6.70
Vertex Pharmaceuticals Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Tangible-Book
6.07
6.37
6.58
6.05
6.70
Competitive Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Vertex Pharmaceuticals Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Vertex Pharmaceuticals (Vertex Pharmaceuticals) Business Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VRTX has been successfully added to your 